HIV molecular immunology database
Found 6 matching records:
| HXB2 Location | Gag(21-35) | Gag Epitope Map
View variants at this location |
||||
|---|---|---|---|---|---|---|
| Epitope |
LRPGGKKKYKLKHIV
|
Epitope Alignment | ||||
| Variants |
|
|||||
| Species (MHC/HLA) | human(B*08) | |||||
Showing all: 1 variant(s).
| Variant ID. | 2594 |
|---|---|
| Epitope Seq. | LRPGGKKKYKLKHIV |
| Variant Seq. | LRPGGKKqYKLKHIV |
| Mutations | K/Q |
| Epitope Location | K8Q |
| HXB2 Location | K28Q |
| Mutation Type | SF: susceptible form |
| Method | CD8 T-cell Elispot - IFNy |
| Note | CTL response to variant LRPGGKKqYKLKHIV was also detected 48 weeks after TI began. |
Schweighardt2010 Becky Schweighardt, Terri Wrin, Duncan A. Meiklejohn, Gerald Spotts, Christos J. Petropoulos, Douglas F. Nixon, and Frederick M. Hecht. Immune Escape Mutations Detected within HIV-1 Epitopes Associated with Viral Control During Treatment Interruption. J. Acquir. Immune Defic. Syndr., 53(1):36-46, Jan 2010. PubMed ID: 19910798. Show all entries for this paper.
| HXB2 Location | Gag(28-36) | Gag Epitope Map
View variants at this location |
||||
|---|---|---|---|---|---|---|
| Epitope |
KYKLKHIVW
|
Epitope Alignment | ||||
| Variants |
|
|||||
| Species (MHC/HLA) | human(A*23) | |||||
Showing all: 1 variant(s).
| Variant ID. | 2595 |
|---|---|
| Epitope Seq. | KYKLKHIVW |
| Variant Seq. | qYKLKHIVW |
| Mutations | K/Q |
| Epitope Location | K1Q |
| HXB2 Location | K28Q |
| Mutation Type | SF: susceptible form |
| Method | CD8 T-cell Elispot - IFNy |
| Note | Gag variant qYKLKHIVW also elicited CTL response 48 weeks after start of TI in Patient 311. |
Schweighardt2010 Becky Schweighardt, Terri Wrin, Duncan A. Meiklejohn, Gerald Spotts, Christos J. Petropoulos, Douglas F. Nixon, and Frederick M. Hecht. Immune Escape Mutations Detected within HIV-1 Epitopes Associated with Viral Control During Treatment Interruption. J. Acquir. Immune Defic. Syndr., 53(1):36-46, Jan 2010. PubMed ID: 19910798. Show all entries for this paper.
| HXB2 Location | Gag(71-79) | Gag Epitope Map
View variants at this location |
||||
|---|---|---|---|---|---|---|
| Epitope |
GSEELKSLY
|
Epitope Alignment | ||||
| Variants |
|
|||||
| Species (MHC/HLA) | human(A*01) | |||||
Showing all: 1 variant(s).
| Variant ID. | 2597 |
|---|---|
| Epitope Seq. | GSEELKSLY |
| Variant Seq. | GSEELrSLY |
| Mutations | K/R |
| Epitope Location | K6R |
| HXB2 Location | K76R |
| Mutation Type | SF: susceptible form |
| Method | CD8 T-cell Elispot - IFNy |
| Note | Gag variant GSEELrSLY also elicited CTL responses all through TI in Patient 311. |
Schweighardt2010 Becky Schweighardt, Terri Wrin, Duncan A. Meiklejohn, Gerald Spotts, Christos J. Petropoulos, Douglas F. Nixon, and Frederick M. Hecht. Immune Escape Mutations Detected within HIV-1 Epitopes Associated with Viral Control During Treatment Interruption. J. Acquir. Immune Defic. Syndr., 53(1):36-46, Jan 2010. PubMed ID: 19910798. Show all entries for this paper.
| HXB2 Location | Gag(74-82) | Gag Epitope Map
View variants at this location |
||||
|---|---|---|---|---|---|---|
| Epitope |
ELKSLYNTV
|
Epitope Alignment | ||||
| Variants |
|
|||||
| Species (MHC/HLA) | human(B*08) | |||||
Showing all: 1 variant(s).
| Variant ID. | 2601 |
|---|---|
| Epitope Seq. | ELKSLYNTV |
| Variant Seq. | ELrSLYNTV |
| Mutations | K/R |
| Epitope Location | K3R |
| HXB2 Location | K76R |
| Mutation Type | SF: susceptible form |
| Method | CD8 T-cell Elispot - IFNy |
| Note | Gag variant ELrSLYNTV also was recognized through TI in Patient 311. |
Schweighardt2010 Becky Schweighardt, Terri Wrin, Duncan A. Meiklejohn, Gerald Spotts, Christos J. Petropoulos, Douglas F. Nixon, and Frederick M. Hecht. Immune Escape Mutations Detected within HIV-1 Epitopes Associated with Viral Control During Treatment Interruption. J. Acquir. Immune Defic. Syndr., 53(1):36-46, Jan 2010. PubMed ID: 19910798. Show all entries for this paper.
| HXB2 Location | Gag(82-92) | Gag Epitope Map
View variants at this location |
||||
|---|---|---|---|---|---|---|
| Epitope |
VATLYCVHQRI
|
Epitope Alignment | ||||
| Variants |
|
|||||
| Species (MHC/HLA) | human(A*11) | |||||
Showing all: 1 variant(s).
| Variant ID. | 2600 |
|---|---|
| Epitope Seq. | VATLYCVHQRI |
| Variant Seq. | VvTLYCVHQRI |
| Mutations | A/V |
| Epitope Location | A2V |
| HXB2 Location | A83V |
| Mutation Type | SF: susceptible form |
| Method | CD8 T-cell Elispot - IFNy |
| Note | Gag variant at anchor position 2, VvTLYCVHQRI, also elicited CTL response but from week 24 after TI began in Patient 313. |
Schweighardt2010 Becky Schweighardt, Terri Wrin, Duncan A. Meiklejohn, Gerald Spotts, Christos J. Petropoulos, Douglas F. Nixon, and Frederick M. Hecht. Immune Escape Mutations Detected within HIV-1 Epitopes Associated with Viral Control During Treatment Interruption. J. Acquir. Immune Defic. Syndr., 53(1):36-46, Jan 2010. PubMed ID: 19910798. Show all entries for this paper.
| HXB2 Location | Gag(93-101) | Gag Epitope Map
View variants at this location |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Epitope |
EIKDTKEAL
|
Epitope Alignment | |||||||
| Variants |
|
||||||||
| Species (MHC/HLA) | human(B*08) | ||||||||
Showing all: 2 variant(s).
| Variant ID. | 2598 |
|---|---|
| Epitope Seq. | EIKDTKEAL |
| Variant Seq. | EvKDTKEAL |
| Mutations | I/V |
| Epitope Location | I2V |
| HXB2 Location | I94V |
| Mutation Type | SF: susceptible form |
| Method | CD8 T-cell Elispot - IFNy |
| Note | Gag variant EvKDTKEAL was recognized by CTL 48 weeks into TI, in Patient 311. |
| Variant ID. | 2599 |
|---|---|
| Epitope Seq. | EIKDTKEAL |
| Variant Seq. | dvKDTKEAL |
| Mutations | E/D I/V |
| Epitope Location | E1D I2V |
| HXB2 Location | E93D I94V |
| Mutation Type | SF: susceptible form |
| Method | CD8 T-cell Elispot - IFNy |
| Note | Gag variant dvKDTKEAL was recognized by CTL 48 weeks into TI, in Patient 311. |
Schweighardt2010 Becky Schweighardt, Terri Wrin, Duncan A. Meiklejohn, Gerald Spotts, Christos J. Petropoulos, Douglas F. Nixon, and Frederick M. Hecht. Immune Escape Mutations Detected within HIV-1 Epitopes Associated with Viral Control During Treatment Interruption. J. Acquir. Immune Defic. Syndr., 53(1):36-46, Jan 2010. PubMed ID: 19910798. Show all entries for this paper.